Content area

Abstract

Background/Objective: Little information is available on the stability and quality controls of compounded 40% dextrose gel required to ensure its safe use in the treatment and prevention of neonatal hypoglycemia. Whether its efficacy relies on buccal absorption also remains uncertain. This study investigates the stability, microbiological safety, rheological properties and dextrose diffusion of a compounded 40% oral dextrose gel, ensuring it can be widely compounded and stored for clinical use. Methods: A 40% dextrose gel compounded with anhydrous dextrose, carboxymethylcellulose, citric acid, sorbic acid and sterile water was subjected to quality control measures including a dextrose content assay, degradation product analysis, microbiological testing and preservative efficacy. Stability studies were conducted at refrigerated (4–8 °C) and ambient temperatures for 7 days and 3 months, respectively. Rheological properties were assessed, and dextrose permeation was measured through an artificial membrane model that mimics a biological membrane. Results: The compounded gel demonstrated stability for up to 7 days at ambient temperature and 90 days when refrigerated. The dextrose content remained within the acceptable range (90–110%) and microbiological tests confirmed compliance with safety standards. The gel exhibited the consistent rheological properties and shear-thinning behavior appropriate for oral mucosal administration. In vitro permeation studies showed no evidence of dextrose diffusion with a long lag time followed by a low steady-state permeation flux. Conclusions: This study validates the compounding process of a stable 40% oral dextrose gel formulation for neonatal hypoglycemia management, which meets quality control criteria and can be safely administered in clinical practice, offering a cost-effective and safe alternative for neonatal care.

Details

1009240
Business indexing term
Location
Title
Formulation, Quality Control and Stability Study of Pediatric Oral Dextrose Gel
Author
Lamy, Edouard 1 ; Orneto, Caroline 2 ; Oumil Her Abdou Ali 3 ; Kireche, Lyna 3 ; Mathias, Fanny 4 ; Bouguergour, Cyrielle 5   VIAFID ORCID Logo  ; Peyron, Florence 5 ; Primas, Nicolas 6   VIAFID ORCID Logo  ; Sauzet, Christophe 2   VIAFID ORCID Logo  ; Piccerelle, Philippe 2 ; Maillotte, Anne-Marie 7 ; Brevaut-Malaty, Veronique 8   VIAFID ORCID Logo  ; Rathelot, Pascal 6   VIAFID ORCID Logo  ; Vanelle, Patrice 6 ; Curti, Christophe 6 

 Service Central de la Qualité et de L’information Pharmaceutiques (SCQIP), Pharmacy Department, Assistance Publique-Hôpitaux de Marseille, 13005 Marseille, France; [email protected] (O.H.A.A.); [email protected] (L.K.); [email protected] (N.P.); [email protected] (P.R.); [email protected] (P.V.); [email protected] (C.C.); UMR 7287 CNRS, Institut des Sciences du Mouvement ISM, Faculté des Sciences du Sport, Aix-Marseille University, 13288 Marseille, France 
 CNRS, IRD, IMBE, Avignon University, Aix Marseille University, 13397 Marseille, France; [email protected] (C.O.); [email protected] (C.S.); [email protected] (P.P.) 
 Service Central de la Qualité et de L’information Pharmaceutiques (SCQIP), Pharmacy Department, Assistance Publique-Hôpitaux de Marseille, 13005 Marseille, France; [email protected] (O.H.A.A.); [email protected] (L.K.); [email protected] (N.P.); [email protected] (P.R.); [email protected] (P.V.); [email protected] (C.C.) 
 CNRS, Institut de Chimie Radicalaire ICR, UMR 7273, Equipe de Pharmaco-Chimie Radicalaire, Aix-Marseille University, 13015 Marseille, France; [email protected]; Pharmacy Department, Marseille Nord University Hospital Pharmacy, Assistance Publique-Hôpitaux de Marseille, 13015 Marseille, France; [email protected] (C.B.); [email protected] (F.P.) 
 Pharmacy Department, Marseille Nord University Hospital Pharmacy, Assistance Publique-Hôpitaux de Marseille, 13015 Marseille, France; [email protected] (C.B.); [email protected] (F.P.) 
 Service Central de la Qualité et de L’information Pharmaceutiques (SCQIP), Pharmacy Department, Assistance Publique-Hôpitaux de Marseille, 13005 Marseille, France; [email protected] (O.H.A.A.); [email protected] (L.K.); [email protected] (N.P.); [email protected] (P.R.); [email protected] (P.V.); [email protected] (C.C.); CNRS, Institut de Chimie Radicalaire ICR, UMR 7273, Equipe de Pharmaco-Chimie Radicalaire, Aix-Marseille University, 13015 Marseille, France; [email protected] 
 Department of Neonatology, Larchet University Hospital, 06200 Nice, France; [email protected] 
 Department of Neonatology, Marseille Nord University Hospital, Assistance Publique-Hôpitaux de Marseille, 13015 Marseille, France; [email protected] 
Publication title
Volume
18
Issue
2
First page
204
Publication year
2025
Publication date
2025
Publisher
MDPI AG
Place of publication
Basel
Country of publication
Switzerland
Publication subject
e-ISSN
14248247
Source type
Scholarly Journal
Language of publication
English
Document type
Journal Article
Publication history
 
 
Online publication date
2025-02-03
Milestone dates
2024-12-30 (Received); 2025-01-30 (Accepted)
Publication history
 
 
   First posting date
03 Feb 2025
ProQuest document ID
3171210477
Document URL
https://www.proquest.com/scholarly-journals/formulation-quality-control-stability-study/docview/3171210477/se-2?accountid=208611
Copyright
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Last updated
2025-03-06
Database
2 databases
  • ProQuest One Academic
  • ProQuest One Academic